<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 29 Aug 2024 10:10:46 +0000</lastbuilddate>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39196588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 28. doi: 10.1001/jamacardio.2024.2574. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39196588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39196588</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2574>10.1001/jamacardio.2024.2574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39196588</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefano Savonitto</dc:creator>
<dc:creator>Patrizio Sarto</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest</dc:title>
<dc:identifier>pmid:39196588</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2574</dc:identifier>
</item>
<item>
<title>Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39196584/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 28. doi: 10.1001/jamacardio.2024.2654. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39196584/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39196584</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2654>10.1001/jamacardio.2024.2654</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39196584</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica A Regan</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Senthil Selvaraj</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection</dc:title>
<dc:identifier>pmid:39196584</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2654</dc:identifier>
</item>
<item>
<title>Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39196578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 28. doi: 10.1001/jamacardio.2024.2577. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39196578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39196578</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2577>10.1001/jamacardio.2024.2577</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39196578</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Pilgrim</dc:creator>
<dc:creator>Martina Rothenbühler</dc:creator>
<dc:creator>Kunjang Sherpa</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Comment on Risk of Cardiac Arrhythmias Among Climbers on Mount Everest-Reply</dc:title>
<dc:identifier>pmid:39196578</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2577</dc:identifier>
</item>
<item>
<title>Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39196575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This study found that approximately 1 in 1000 UKB participants were LP/P TTR variant carriers, exceeding previously reported prevalence. The findings emphasize the need for clinical vigilance in identifying individuals at risk of developing vATTR and associated poor outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 28. doi: 10.1001/jamacardio.2024.2190. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The population prevalence of cardiac transthyretin amyloidosis (ATTR) caused by pathogenic variation in the TTR gene (vATTR) is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To estimate the population prevalence of disease-causing TTR variants and evaluate associated phenotypes and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study analyzed UK Biobank (UKB) participants with whole-exome sequencing, electrocardiogram, and cardiovascular magnetic resonance data. Participants were enrolled from 2006 to 2010, with a median follow-up of 12 (IQR, 11-13) years (cutoff date for the analysis, March 12, 2024). Sixty-two candidate TTR variants were extracted based on rarity (minor allele frequency ≤0.0001) and/or previously described associations with amyloidosis if more frequent.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Carrier status for TTR variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Associations of TTR carrier status with vATTR prevalence and cardiovascular imaging and electrocardiogram traits were explored using descriptive statistics. Associations between TTR carrier status and atrial fibrillation, conduction disease, heart failure, and all-cause mortality were evaluated using adjusted Cox proportional hazards models. Genotypic and diagnostic concordance was examined using International Statistical Classification of Diseases, Tenth Revision codes from the hospital record.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The overall cohort included 469 789 UKB participants (mean [SD] age, 56.5 [8.1] years; 54.2% female and 45.8% male). A likely pathogenic/pathogenic (LP/P) TTR variant was detected in 473 (0.1%) participants, with Val142Ile being the most prevalent (367 [77.6%]); 91 individuals (0.02%) were carriers of a variant of unknown significance . The overall prevalence of LP/P variants was 0.02% (105 of 444 243) in participants with European ancestry and 4.3% (321 of 7533) in participants with African ancestry. The LP/P variants were associated with higher left ventricular mass indexed to body surface area (β = 4.66; 95% CI, 1.87-7.44), and Val142Ile was associated with a longer PR interval (β = 18.34; 95% CI, 5.41-31.27). The LP/P carrier status was associated with a higher risk of heart failure (hazard ratio [HR], 2.68; 95% CI, 1.75-4.12) and conduction disease (HR, 1.88; 95% CI, 1.25-2.83). Higher all-cause mortality risk was observed for non-Val142Ile LP/P variants (HR, 1.98; 95% CI, 1.06-3.67). Thirteen participants (2.8%) with LP/P variants had diagnostic codes compatible with cardiac or neurologic amyloidosis. Variants of unknown significance were not associated with outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study found that approximately 1 in 1000 UKB participants were LP/P TTR variant carriers, exceeding previously reported prevalence. The findings emphasize the need for clinical vigilance in identifying individuals at risk of developing vATTR and associated poor outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39196575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39196575</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2190>10.1001/jamacardio.2024.2190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39196575</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Hannah L Nicholls</dc:creator>
<dc:creator>C Anwar A Chahal</dc:creator>
<dc:creator>Mohammed Y Khanji</dc:creator>
<dc:creator>Elisa Rauseo</dc:creator>
<dc:creator>Sucharitha Chadalavada</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Patricia B Munroe</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Luis R Lopes</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population</dc:title>
<dc:identifier>pmid:39196575</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2190</dc:identifier>
</item>
<item>
<title>Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39193886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SMuRF-less patients with stable CAD have a substantial but significantly lower 5-year rate of CV death or non-fatal MI than patients with risk factors. The risk of CV outcomes increases steadily with the number of risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 12;45(27):2396-2406. doi: 10.1093/eurheartj/ehae299.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: It has been reported that patients without standard modifiable cardiovascular (CV) risk factors (SMuRFs-diabetes, dyslipidaemia, hypertension, and smoking) presenting with first myocardial infarction (MI), especially women, have a higher in-hospital mortality than patients with risk factors, and possibly a lower long-term risk provided they survive the post-infarct period. This study aims to explore the long-term outcomes of SMuRF-less patients with stable coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: CLARIFY is an observational cohort of 32 703 outpatients with stable CAD enrolled between 2009 and 2010 in 45 countries. The baseline characteristics and clinical outcomes of patients with and without SMuRFs were compared. The primary outcome was a composite of 5-year CV death or non-fatal MI. Secondary outcomes were 5-year all-cause mortality and major adverse cardiovascular events (MACE-CV death, non-fatal MI, or non-fatal stroke).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 22 132 patients with complete risk factor and outcome information, 977 (4.4%) were SMuRF-less. Age, sex, and time since CAD diagnosis were similar across groups. SMuRF-less patients had a lower 5-year rate of CV death or non-fatal MI (5.43% [95% CI 4.08-7.19] vs. 7.68% [95% CI 7.30-8.08], P = 0.012), all-cause mortality, and MACE. Similar results were found after adjustments. Clinical event rates increased steadily with the number of SMuRFs. The benefit of SMuRF-less status was particularly pronounced in women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SMuRF-less patients with stable CAD have a substantial but significantly lower 5-year rate of CV death or non-fatal MI than patients with risk factors. The risk of CV outcomes increases steadily with the number of risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39193886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39193886</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae299>10.1093/eurheartj/ehae299</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39193886</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Guillaume Roger</dc:creator>
<dc:creator>Grégory Ducrocq</dc:creator>
<dc:creator>Jules Mesnier</dc:creator>
<dc:creator>Neila Sayah</dc:creator>
<dc:creator>Jérémie Abtan</dc:creator>
<dc:creator>Roberto Ferrari</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Kim M Fox</dc:creator>
<dc:creator>Jean-Claude Tardif</dc:creator>
<dc:creator>Michal Tendera</dc:creator>
<dc:creator>Laurent J Feldman</dc:creator>
<dc:creator>Yedid Elbez</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>CLARIFY Investigators</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry</dc:title>
<dc:identifier>pmid:39193886</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae299</dc:identifier>
</item>
<item>
<title>Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39193814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 28:ehae542. doi: 10.1093/eurheartj/ehae542. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39193814/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39193814</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae542>10.1093/eurheartj/ehae542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39193814</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution</dc:title>
<dc:identifier>pmid:39193814</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae542</dc:identifier>
</item>
<item>
<title>Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39193812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 28:ehae543. doi: 10.1093/eurheartj/ehae543. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39193812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39193812</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae543>10.1093/eurheartj/ehae543</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39193812</guid>
<pubDate>Wed, 28 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefano Ministrini</dc:creator>
<dc:creator>Amedeo Tirandi</dc:creator>
<dc:date>2024-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk</dc:title>
<dc:identifier>pmid:39193812</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae543</dc:identifier>
</item>
<item>
<title>A line attractor encoding a persistent internal state requires neuropeptide signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39191257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>Internal states drive survival behaviors, but their neural implementation is poorly understood. Recently, we identified a line attractor in the ventromedial hypothalamus (VMH) that represents a state of aggressiveness. Line attractors can be implemented by recurrent connectivity or neuromodulatory signaling, but evidence for the latter is scant. Here, we demonstrate that neuropeptidergic signaling is necessary for line attractor dynamics in this system by using cell-type-specific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 22:S0092-8674(24)00906-1. doi: 10.1016/j.cell.2024.08.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Internal states drive survival behaviors, but their neural implementation is poorly understood. Recently, we identified a line attractor in the ventromedial hypothalamus (VMH) that represents a state of aggressiveness. Line attractors can be implemented by recurrent connectivity or neuromodulatory signaling, but evidence for the latter is scant. Here, we demonstrate that neuropeptidergic signaling is necessary for line attractor dynamics in this system by using cell-type-specific CRISPR-Cas9-based gene editing combined with single-cell calcium imaging. Co-disruption of receptors for oxytocin and vasopressin in adult VMH Esr1<sup>+</sup> neurons that control aggression diminished attack, reduced persistent neural activity, and eliminated line attractor dynamics while only slightly reducing overall neural activity and sex- or behavior-specific tuning. These data identify a requisite role for neuropeptidergic signaling in implementing a behaviorally relevant line attractor in mammals. Our approach should facilitate mechanistic studies in neuroscience that bridge different levels of biological function and abstraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39191257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39191257</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.015>10.1016/j.cell.2024.08.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39191257</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>George Mountoufaris</dc:creator>
<dc:creator>Aditya Nair</dc:creator>
<dc:creator>Bin Yang</dc:creator>
<dc:creator>Dong-Wook Kim</dc:creator>
<dc:creator>Amit Vinograd</dc:creator>
<dc:creator>Samuel Kim</dc:creator>
<dc:creator>Scott W Linderman</dc:creator>
<dc:creator>David J Anderson</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A line attractor encoding a persistent internal state requires neuropeptide signaling</dc:title>
<dc:identifier>pmid:39191257</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.015</dc:identifier>
</item>
<item>
<title>Congress wrap-up: ESC Preventive Cardiology 2024 in Athens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39190608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae329. doi: 10.1093/eurheartj/ehae329. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39190608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39190608</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae329>10.1093/eurheartj/ehae329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39190608</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolle Kränkel</dc:creator>
<dc:creator>Guido Claessen</dc:creator>
<dc:creator>Ana Abreu</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Congress wrap-up: ESC Preventive Cardiology 2024 in Athens</dc:title>
<dc:identifier>pmid:39190608</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae329</dc:identifier>
</item>
<item>
<title>The revolution will be digital: a wake-up call from Helsinki's Radical Health Festival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39190480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae473. doi: 10.1093/eurheartj/ehae473. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39190480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39190480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae473>10.1093/eurheartj/ehae473</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39190480</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The revolution will be digital: a wake-up call from Helsinki's Radical Health Festival</dc:title>
<dc:identifier>pmid:39190480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae473</dc:identifier>
</item>
<item>
<title>European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39189413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 27:ehae466. doi: 10.1093/eurheartj/ehae466. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were collected by questionnaire circulated to the national cardiac societies of ESC member countries. Statistics pertaining to 2022, or latest available year, are presented. New material in this report includes contemporary estimates of the economic burden of CVD and mortality statistics for a range of CVD phenotypes. CVD accounts for 11% of the EU's total healthcare expenditure. It remains the most common cause of death in ESC member countries with over 3 million deaths per year. Proportionately more deaths from CVD occur in middle-income compared with high-income countries in both females (53% vs. 34%) and males (46% vs. 30%). Between 1990 and 2021, median age-standardized mortality rates (ASMRs) for CVD decreased by median >;50% in high-income ESC member countries but in middle-income countries the median decrease was &lt;12%. These inequalities between middle- and high-income ESC member countries likely reflect heterogeneous exposures to a range of environmental, socioeconomic, and clinical risk factors. The 2023 survey suggests that treatment factors may also contribute with middle-income countries reporting lower rates per million of percutaneous coronary intervention (1355 vs. 2330), transcatheter aortic valve implantation (4.0 vs. 153.4) and pacemaker implantation (147.0 vs. 831.9) compared with high-income countries. The ESC Atlas 2023 report shows continuing inequalities in the epidemiology and management of CVD between middle-income and high-income ESC member countries. These inequalities are exemplified by the changes in CVD ASMRs during the last 30 years. In the high-income ESC member countries, ASMRs have been in steep decline during this period but in the middle-income countries declines have been very small. There is now an important need for targeted action to reduce the burden of CVD, particularly in those countries where the burden is greatest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39189413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39189413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae466>10.1093/eurheartj/ehae466</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39189413</guid>
<pubDate>Tue, 27 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam Timmis</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Nick Townsend</dc:creator>
<dc:creator>Aleksandra Torbica</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Radu Huculeci</dc:creator>
<dc:creator>Denis Kazakiewicz</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Efstratios Karagiannidis</dc:creator>
<dc:creator>Marta Cvijic</dc:creator>
<dc:creator>Agnieszka Kapłon-Cieślicka</dc:creator>
<dc:creator>Barbara Ignatiuk</dc:creator>
<dc:creator>Pekka Raatikainen</dc:creator>
<dc:creator>Delphine De Smedt</dc:creator>
<dc:creator>Angela Wood</dc:creator>
<dc:creator>Dariusz Dudek</dc:creator>
<dc:creator>Eric Van Belle</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:creator>ESC National Cardiac Societies</dc:creator>
<dc:date>2024-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics</dc:title>
<dc:identifier>pmid:39189413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae466</dc:identifier>
</item>
<item>
<title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):706-709. doi: 10.1161/CIRCULATIONAHA.124.070464. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186532</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070464>10.1161/CIRCULATIONAHA.124.070464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186532</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Constance Delwarde</dc:creator>
<dc:creator>Masanori Aikawa</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Mouse Model of Late-Stage Coronary Atherosclerosis With Features of Plaque Rupture and Stroke</dc:title>
<dc:identifier>pmid:39186532</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070464</dc:identifier>
</item>
<item>
<title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional medications. DNA- and RNA-based therapeutics have the potential to transform the care of patients with FH. Recent advances are overcoming obstacles to clinical translation of nucleic acid-based medications, including greater stability of the formulations as well as site-specific delivery, making gene-based therapy for FH an alternative approach for treatment of FH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186530</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11349040/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">PMC11349040</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067957>10.1161/CIRCULATIONAHA.123.067957</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186530</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tulsi R Damase</dc:creator>
<dc:creator>Roman Sukhovershin</dc:creator>
<dc:creator>Biana Godin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>John P Cooke</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:39186530</dc:identifier>
<dc:identifier>pmc:PMC11349040</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067957</dc:identifier>
</item>
<item>
<title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):738-741. doi: 10.1161/CIRCULATIONAHA.123.067438. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186529/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186529</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067438>10.1161/CIRCULATIONAHA.123.067438</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186529</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariaelena Valentino</dc:creator>
<dc:creator>Matteo Malinverno</dc:creator>
<dc:creator>Claudio Maderna</dc:creator>
<dc:creator>Van-Cuong Pham</dc:creator>
<dc:creator>Claudia Jasmin Rödel</dc:creator>
<dc:creator>Federica Zanardi</dc:creator>
<dc:creator>Maximiliano Arce</dc:creator>
<dc:creator>Lorenzo Drufuca</dc:creator>
<dc:creator>Grazisa Rossetti</dc:creator>
<dc:creator>Peetra U Magnusson</dc:creator>
<dc:creator>Maria Grazia Lampugnani</dc:creator>
<dc:creator>Elisabetta Dejana</dc:creator>
<dc:creator>Salim Abdelilah-Seyfried</dc:creator>
<dc:creator>Massimiliano Pagani</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations</dc:title>
<dc:identifier>pmid:39186529</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067438</dc:identifier>
</item>
<item>
<title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e201-e202. doi: 10.1161/CIRCULATIONAHA.124.069703. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186528</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069703>10.1161/CIRCULATIONAHA.124.069703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186528</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Puneeth Shridhar</dc:creator>
<dc:creator>Soumojit Pal</dc:creator>
<dc:creator>Nicolas G Clavere</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186528</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069703</dc:identifier>
</item>
<item>
<title>Perspectives on Heart Valve Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):661-662. doi: 10.1161/CIRCULATIONAHA.124.070262. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186527/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186527</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070262>10.1161/CIRCULATIONAHA.124.070262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186527</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tirone E David</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Perspectives on Heart Valve Repair</dc:title>
<dc:identifier>pmid:39186527</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070262</dc:identifier>
</item>
<item>
<title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):e200. doi: 10.1161/CIRCULATIONAHA.123.068349. Epub 2024 Aug 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186526/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186526</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068349>10.1161/CIRCULATIONAHA.123.068349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186526</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Sun</dc:creator>
<dc:creator>Jian Ren</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy"</dc:title>
<dc:identifier>pmid:39186526</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068349</dc:identifier>
</item>
<item>
<title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-Cd36^(fl/-) mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 27;150(9):710-723. doi: 10.1161/CIRCULATIONAHA.123.065005. Epub 2024 Aug 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell-derived exosome nebulization therapy (SCENT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stem cell-derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of <i>Cd36</i> in endothelial cells (ECs). In an EC-<i>Cd36</i><sup>fl/-</sup> conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC-<i>Cd36</i><sup>fl/-</sup> mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39186525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39186525</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11349039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">PMC11349039</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065005>10.1161/CIRCULATIONAHA.123.065005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39186525</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Junlang Li</dc:creator>
<dc:creator>Shenghuan Sun</dc:creator>
<dc:creator>Dashuai Zhu</dc:creator>
<dc:creator>Xuan Mei</dc:creator>
<dc:creator>Yongbo Lyu</dc:creator>
<dc:creator>Ke Huang</dc:creator>
<dc:creator>Yuan Li</dc:creator>
<dc:creator>Shuo Liu</dc:creator>
<dc:creator>Zhenzhen Wang</dc:creator>
<dc:creator>Shiqi Hu</dc:creator>
<dc:creator>Halle J Lutz</dc:creator>
<dc:creator>Kristen D Popowski</dc:creator>
<dc:creator>Phuong-Uyen C Dinh</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Ke Cheng</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction</dc:title>
<dc:identifier>pmid:39186525</dc:identifier>
<dc:identifier>pmc:PMC11349039</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065005</dc:identifier>
</item>
<item>
<title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093/eurheartj/ehae479. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin &lt; 100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation &lt; 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5-93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07-0.96; P = .043) was lower with FCM than placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39185895</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae479>10.1093/eurheartj/ehae479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185895</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan von Haehling</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Ruben Evertz</dc:creator>
<dc:creator>Tania Garfias-Veitl</dc:creator>
<dc:creator>Carlotta Derad</dc:creator>
<dc:creator>Monika Diek</dc:creator>
<dc:creator>Mahir Karakas</dc:creator>
<dc:creator>Ralf Birkemeyer</dc:creator>
<dc:creator>Gerasimos Fillippatos</dc:creator>
<dc:creator>Mitja Lainscak</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial</dc:title>
<dc:identifier>pmid:39185895</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae479</dc:identifier>
</item>
<item>
<title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093/eurheartj/ehae490. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39185864</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae490>10.1093/eurheartj/ehae490</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185864</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Veraprapas Kittipibul</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?</dc:title>
<dc:identifier>pmid:39185864</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae490</dc:identifier>
</item>
<item>
<title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240829061045&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 26:ehae525. doi: 10.1093/eurheartj/ehae525. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To explore male-female differences in aneurysm growth and clinical outcomes in a two-centre retrospective Dutch cohort study of adult patients with ascending aortic aneurysm (AscAA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adult patients in whom imaging of an AscAA (root and/or ascending: ≥40 mm) was performed between 2007 and 2022 were included. Aneurysm growth was analysed using repeated measurements at the sinuses of Valsalva (SoV) and tubular ascending aorta. Male-female differences were explored in presentation, aneurysm characteristics, treatment strategy, survival, and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: One thousand eight hundred and fifty-eight patients were included (31.6% female). Median age at diagnosis was 65.4 years (interquartile range: 53.4-71.7) for females and 59.0 years (interquartile range: 49.3-68.0) for males (P &lt; .001). At diagnosis, females more often had tubular ascending aortic involvement (75.5% vs. 70.2%; P = .030) while males more often had SoV involvement (42.8% vs. 21.6%; P &lt; .001). Maximum absolute aortic diameter, at any location, at diagnosis did not differ between females (45.0 mm) and males (46.5 mm; P = .388). In females, tubular ascending growth was faster (P &lt; .001), whereas in males, SoV growth was faster (P = .005), corrected for covariates. Unadjusted 10-year survival was 72.5% [95% confidence interval (CI) 67.8%-77.6%] for females and 78.3% (95% CI 75.3%-81.3%) for males (P = .010). Twenty-three type A dissections occurred, with an incidence rate of 8.2/1000 patient-years (95% CI 4.4-14.1) in females and 2.4/1000 patient-years (95% CI 1.2-4.5) in males [incidence rate ratio females/males: 3.4 (95% CI 1.5-8.0; P = .004)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients having entered a diagnostic programme, involvement of aortic segments and age- and segment-related growth patterns differ between women and men with AscAA, particularly at an older age. Unravelling of these intertwined observations will provide a deeper understanding of AscAA progression and outcome in women and men and can be used as an evidence base for patient-tailored clinical guideline development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39185705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240829061045&v=2.18.0.post9+e462414">39185705</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae525>10.1093/eurheartj/ehae525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39185705</guid>
<pubDate>Mon, 26 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Maximiliaan L Notenboom</dc:creator>
<dc:creator>Adine R de Keijzer</dc:creator>
<dc:creator>Kevin M Veen</dc:creator>
<dc:creator>Arjen Gökalp</dc:creator>
<dc:creator>Ad J J C Bogers</dc:creator>
<dc:creator>Robin H Heijmen</dc:creator>
<dc:creator>Roland R J van Kimmenade</dc:creator>
<dc:creator>Guillaume S C Geuzebroek</dc:creator>
<dc:creator>M Mostafa Mokhles</dc:creator>
<dc:creator>Jos A Bekkers</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:creator>Johanna J M Takkenberg</dc:creator>
<dc:date>2024-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-related differences in the clinical course of aortic root and ascending aortic aneurysms: the DisSEXion Study</dc:title>
<dc:identifier>pmid:39185705</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae525</dc:identifier>
</item>





























</channel>
</rss>